News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Release: Treatment With PROVENGE® (Sipuleucel-T) Induces Antigen Spread Associated With Overall Survival Benefits In Advanced Prostate Cancer



5/20/2014 10:18:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE--(BUSINESS WIRE)--May 20, 2014-Dendreon Corporation (NASDAQ: DNDN) today announced the presentation of data from the ProACT and IMPACT studies suggesting that PROVENGE® (sipuleucel-T) elicits an immune response associated with an overall survival benefit. Also being presented are data from the PROCEED registry suggesting similar treatment patterns for urologists and oncologists in PROVENGE-treated patients with metastatic castration-resistant prostate cancer (mCRPC). The ProACT and IMPACT data will be reported in a podium presentation and the PROCEED data will be included in a general poster session during the 2014 American Urological Association (AUA) Annual Meeting from May 16-21, 2014 in Orlando, Florida.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES